# NEUROONE MEDICAL TECHNOLOGIES Corp: financial statements, quarterly

NMTC · Nasdaq · CIK 1500198 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/nmtc.md) · [Financials](/companies/nmtc/financials.md) · [Filings](/companies/nmtc/filings.md) · [Insiders](/companies/nmtc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nmtc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [742 d](/filings/0001213900-24-109524.md) | [978](/filings/0001213900-25-012511.md) | [1,377](/filings/0001213900-25-042266.md) | [826](/filings/0001213900-25-076080.md) | [272 d](/filings/0001213900-25-122390.md) | [3,274](/filings/0001213900-26-016860.md) | [1,387](/filings/0001213900-26-068307.md) | [1,696](/filings/0001213900-26-088724.md) | [2,741 d](/filings/0001213900-25-122390.md) | [2,893](/filings/0001213900-26-016860.md) | [1,862](/filings/0001213900-26-068307.md) | [1,973](/filings/0001213900-26-088724.md) |
| Cost of revenue | $k | [548 d](/filings/0001213900-24-109524.md) | [711](/filings/0001213900-25-012511.md) | [987](/filings/0001213900-25-042266.md) | [544](/filings/0001213900-25-076080.md) | [131 d](/filings/0001213900-25-122390.md) | [1,347](/filings/0001213900-26-016860.md) | [615](/filings/0001213900-26-068307.md) | [781](/filings/0001213900-26-088724.md) | [1,212 d](/filings/0001213900-25-122390.md) | [1,325](/filings/0001213900-26-016860.md) | [872](/filings/0001213900-26-068307.md) | [790](/filings/0001213900-26-088724.md) |
| Gross profit | $k | [194 d](/filings/0001213900-24-109524.md) | [266](/filings/0001213900-25-012511.md) | [390](/filings/0001213900-25-042266.md) | [282](/filings/0001213900-25-076080.md) | [141 d](/filings/0001213900-25-122390.md) | [1,927](/filings/0001213900-26-016860.md) | [771](/filings/0001213900-26-068307.md) | [915](/filings/0001213900-26-088724.md) | [1,529 d](/filings/0001213900-25-122390.md) | [1,568](/filings/0001213900-26-016860.md) | [990](/filings/0001213900-26-068307.md) | [1,183](/filings/0001213900-26-088724.md) |
| Research and development | $k | [1,779 d](/filings/0001213900-24-109524.md) | [1,483](/filings/0001213900-25-012511.md) | [1,274](/filings/0001213900-25-042266.md) | [1,195](/filings/0001213900-25-076080.md) | [1,114 d](/filings/0001213900-25-122390.md) | [1,172](/filings/0001213900-26-016860.md) | [1,511](/filings/0001213900-26-068307.md) | [1,182](/filings/0001213900-26-088724.md) | [1,118 d](/filings/0001213900-25-122390.md) | [1,390](/filings/0001213900-26-016860.md) | [1,468](/filings/0001213900-26-068307.md) | [1,425](/filings/0001213900-26-088724.md) |
| Selling, general and administrative | $k | [1,579 d](/filings/0001213900-24-109524.md) | [2,173](/filings/0001213900-25-012511.md) | [2,003](/filings/0001213900-25-042266.md) | [1,881](/filings/0001213900-25-076080.md) | [1,844 d](/filings/0001213900-25-122390.md) | [2,043](/filings/0001213900-26-016860.md) | [1,940](/filings/0001213900-26-068307.md) | [1,619](/filings/0001213900-26-088724.md) | [1,782 d](/filings/0001213900-25-122390.md) | [1,885](/filings/0001213900-26-016860.md) | [1,919](/filings/0001213900-26-068307.md) | [2,182](/filings/0001213900-26-088724.md) |
| Operating income | $k | [(3,165) d](/filings/0001213900-24-109524.md) | [(3,390)](/filings/0001213900-25-012511.md) | [(2,886)](/filings/0001213900-25-042266.md) | [(2,794)](/filings/0001213900-25-076080.md) | [(2,817) d](/filings/0001213900-25-122390.md) | [1,711](/filings/0001213900-26-016860.md) | [(2,680)](/filings/0001213900-26-068307.md) | [(1,887)](/filings/0001213900-26-088724.md) | [(1,371) d](/filings/0001213900-25-122390.md) | [(1,707)](/filings/0001213900-26-016860.md) | [(2,397)](/filings/0001213900-26-068307.md) | [(2,424)](/filings/0001213900-26-088724.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(3,135) d](/filings/0001213900-24-109524.md) | [(3,345)](/filings/0001213900-25-076080.md) | [(2,855)](/filings/0001213900-25-076080.md) | [(2,768)](/filings/0001213900-25-076080.md) | [(3,351) d](/filings/0001213900-25-122390.md) | [1,785](/filings/0001213900-26-088724.md) | [(2,271)](/filings/0001213900-26-088724.md) | [(1,501)](/filings/0001213900-26-088724.md) | [(1,619) d](/filings/0001213900-25-122390.md) | [(1,438)](/filings/0001213900-26-088724.md) | [(2,382)](/filings/0001213900-26-088724.md) | [(2,006)](/filings/0001213900-26-088724.md) |
| Diluted EPS | $ per share | not reported | [(0.14)](/filings/0001213900-25-012511.md) | [(0.11)](/filings/0001213900-25-042266.md) | [(0.10)](/filings/0001213900-25-076080.md) | not reported | [0.06](/filings/0001213900-26-016860.md) | [(0.44)](/filings/0001213900-26-068307.md) | [(0.19)](/filings/0001213900-26-088724.md) | not reported | [(0.03)](/filings/0001213900-26-016860.md) | [(0.28)](/filings/0001213900-26-068307.md) | [(0.28)](/filings/0001213900-26-088724.md) |
| Basic EPS | $ per share | not reported | [(0.14)](/filings/0001213900-25-012511.md) | [(0.11)](/filings/0001213900-25-042266.md) | [(0.10)](/filings/0001213900-25-076080.md) | not reported | [0.06](/filings/0001213900-26-016860.md) | [(0.44)](/filings/0001213900-26-068307.md) | [(0.19)](/filings/0001213900-26-088724.md) | not reported | [(0.03)](/filings/0001213900-26-016860.md) | [(0.28)](/filings/0001213900-26-068307.md) | [(0.23)](/filings/0001213900-26-088724.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.3](/filings/0001213900-24-109524.md) | [2.7](/filings/0001213900-24-013276.md) | [2.4](/filings/0001213900-24-042948.md) | [1.6](/filings/0001213900-24-068633.md) | [1.5](/filings/0001213900-25-122390.md) | [1.1](/filings/0001213900-25-012511.md) | [1.3](/filings/0001213900-25-042266.md) | [8.0](/filings/0001213900-25-076080.md) | [6.6](/filings/0001213900-26-088724.md) | [3.6](/filings/0001213900-26-016860.md) | [2.8](/filings/0001213900-26-068307.md) | [2.0](/filings/0001213900-26-088724.md) |
| Current assets | $m | [7.3](/filings/0001213900-24-109524.md) | [5.1](/filings/0001213900-24-013276.md) | [4.7](/filings/0001213900-24-042948.md) | [4.1](/filings/0001213900-24-068633.md) | [4.6](/filings/0001213900-25-122390.md) | [5.7](/filings/0001213900-25-012511.md) | [3.8](/filings/0001213900-25-042266.md) | [10.2](/filings/0001213900-25-076080.md) | [10.2](/filings/0001213900-26-088724.md) | [8.1](/filings/0001213900-26-016860.md) | [7.1](/filings/0001213900-26-068307.md) | [5.8](/filings/0001213900-26-088724.md) |
| Total assets | $m | [8.1](/filings/0001213900-24-109524.md) | [5.8](/filings/0001213900-24-013276.md) | [5.4](/filings/0001213900-24-042948.md) | [4.9](/filings/0001213900-24-068633.md) | [5.4](/filings/0001213900-25-122390.md) | [6.5](/filings/0001213900-25-012511.md) | [4.5](/filings/0001213900-25-042266.md) | [10.8](/filings/0001213900-25-076080.md) | [10.8](/filings/0001213900-26-088724.md) | [8.6](/filings/0001213900-26-016860.md) | [7.6](/filings/0001213900-26-068307.md) | [6.2](/filings/0001213900-26-088724.md) |
| Current liabilities | $m | [1.8](/filings/0001213900-24-109524.md) | [1.4](/filings/0001213900-24-013276.md) | [1.5](/filings/0001213900-24-042948.md) | [1.7](/filings/0001213900-24-068633.md) | [2.2](/filings/0001213900-25-122390.md) | [1.6](/filings/0001213900-25-012511.md) | [1.8](/filings/0001213900-25-042266.md) | [1.4](/filings/0001213900-25-076080.md) | [2.3](/filings/0001213900-26-088724.md) | [1.3](/filings/0001213900-26-016860.md) | [1.7](/filings/0001213900-26-068307.md) | [2.0](/filings/0001213900-26-088724.md) |
| Total liabilities | $m | [1.8](/filings/0001213900-24-109524.md) | [1.4](/filings/0001213900-24-013276.md) | [1.5](/filings/0001213900-24-042948.md) | [1.9](/filings/0001213900-24-068633.md) | [4.5](/filings/0001213900-25-122390.md) | [3.6](/filings/0001213900-25-012511.md) | [3.3](/filings/0001213900-25-042266.md) | [2.6](/filings/0001213900-25-076080.md) | [3.7](/filings/0001213900-26-088724.md) | [2.2](/filings/0001213900-26-016860.md) | [2.5](/filings/0001213900-26-068307.md) | [2.4](/filings/0001213900-26-088724.md) |
| Short-term borrowings | $m | [0.1](/filings/0001213900-24-042948.md) | not reported | [0.1](/filings/0001213900-24-042948.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [6.2](/filings/0001213900-25-122390.md) | [4.4](/filings/0001213900-25-076080.md) | [3.9](/filings/0001213900-25-076080.md) | [3.0](/filings/0001213900-25-076080.md) | [0.8](/filings/0001213900-26-088724.md) | [2.9](/filings/0001213900-26-088724.md) | [1.1](/filings/0001213900-26-088724.md) | [8.2](/filings/0001213900-26-088724.md) | [7.1](/filings/0001213900-26-088724.md) | [6.4](/filings/0001213900-26-088724.md) | [5.1](/filings/0001213900-26-088724.md) | [3.8](/filings/0001213900-26-088724.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,903) d](/filings/0001213900-24-109524.md) | [(3,809)](/filings/0001213900-25-012511.md) | [(2,175) d](/filings/0001213900-25-042266.md) | [(2,360) d](/filings/0001213900-25-076080.md) | [(2,667) d](/filings/0001213900-25-122390.md) | [208](/filings/0001213900-26-016860.md) | [(56.1) d](/filings/0001213900-26-068307.md) | [(1,464) d](/filings/0001213900-26-088724.md) | [(1,526) d](/filings/0001213900-25-122390.md) | [(3,116)](/filings/0001213900-26-016860.md) | [(1,329) d](/filings/0001213900-26-068307.md) | [(1,082) d](/filings/0001213900-26-088724.md) |
| Capital expenditure | $k | [57.6 d](/filings/0001213900-24-109524.md) | [37.1](/filings/0001213900-24-013276.md) | [31.4 d](/filings/0001213900-24-042948.md) | [14.8 d](/filings/0001213900-25-076080.md) | [36.9 d](/filings/0001213900-25-122390.md) | [24.4](/filings/0001213900-26-016860.md) | [3.2 d](/filings/0001213900-26-068307.md) | [43.5 d](/filings/0001213900-26-088724.md) | [10.6 d](/filings/0001213900-25-122390.md) | [40.8](/filings/0001213900-26-016860.md) | [38.5 d](/filings/0001213900-26-068307.md) | [19.7 d](/filings/0001213900-26-088724.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [16.2](/filings/0001213900-24-013276.md) | [16.4](/filings/0001213900-24-042948.md) | [17.6](/filings/0001213900-24-068633.md) | [24.0](/filings/0001213900-25-012511.md) | [25.9](/filings/0001213900-25-042266.md) | [27.4](/filings/0001213900-25-076080.md) | [30.9](/filings/0001213900-26-016860.md) | [5.2](/filings/0001213900-26-068307.md) | [8.1](/filings/0001213900-26-088724.md) | [50.3](/filings/0001213900-26-016860.md) | [8.5](/filings/0001213900-26-068307.md) | [8.7](/filings/0001213900-26-088724.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 9,105,763 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001213900-26-088724.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.